Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

Abstract: A pharmaceutical composition comprises a metal nanoparticle having an average diameter of about 0.5 nm to about 5 nm. The composition may be used to treat cancer or an anosmia-related disease.

Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: The present invention relates to the coating of a range of functional heparins onto the surface of a substrate for which hemocompatibility is a key functional characteristic, such that the functionality of the functional heparin is maintained. The approach employs a metal coordination complex to bind to the substrate with the functional heparin binding to the metal coordination complex to thereby impart hemocompatibility.

Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid is provided.

Abstract: A hybrid hydrogel including a hydrogel material and a plurality of first hybrid nanoparticles is provided. The plurality of first hybrid nanoparticles are conjugated to the hydrogel material, wherein each of the first hybrid nanoparticles includes a first positive-charged polysaccharide and a first negative-charged polysaccharide. The first positive-charged polysaccharide is located at an inner core of the first hybrid nanoparticles. The first negative-charged polysaccharide is located at an outer shell of the first hybrid nanoparticles and carries a plurality of first growth factors. The first negative-charged polysaccharide and the first positive-charged polysaccharide are electrostatically attracted to form the first hybrid nanoparticles. A method of fabricating the hybrid hydrogel is also provided.

Abstract: Disclosed are compositions and methods for preparing compositions that improve plant health and reduce fungal infestations. Also disclosed are methods of using the compositions described herein to improve plant health by applying the compositions directly to plants, and/or applying the compositions to substrates used for plant growth. The compositions include a synergistic ratio of composting bacteria, bio-surfactant producing bacteria, bio-remediating bacteria, bovine feces, and humic acid. The compositions reduce fungal growth and fungal infestation the infected area. Methods of reducing brown patch and/or dollar spot infestations to a plant such as turf grass or crop are also described herein.

Abstract: Provided is a herbicidal composition comprising a compound of Formula (I) as a herbicidally active ingredient, and an agronomically acceptable additive, Also provided is a method of controlling undesirable vegetation using the herbicide composition.

Abstract: Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; a preformed emulsion and/or an ionic benefit agent, wherein the ionic benefit agents are those excluding ionic dyes, precursors thereof, and anionic surfactants; an alkyl ether and/or alkyl ester, preferably alkyl ether, of at least one of the following: polyethylene glycol, polypropylene glycol, polyglycerin, and mixtures thereof, and wherein the alkyl ether and/or alkyl ester has from about 50 to about 300 units of ethylene glycol, propylene glycol, glycerin and mixtures thereof; and an aqueous carrier. The composition of the present invention provides benefits from ionic benefit agents and/or preformed emulsions, while maintaining stability and wet conditioning of the composition.

Abstract: A composition comprising microcapsules functionalized with polymerizable functional groups on the surface of said microcapsules wherein the functional groups form covalent bonds with monomers in the continuous phase to enhance the mechanical properties of the composition.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol.

Abstract: Herbicidal concentrate compositions containing a combination of glyphosate salt and dicamba salt are provided. For example, a low volatility aqueous herbicidal concentrate composition including a glyphosate salt, dicamba salt, and a surfactant is described, wherein (i) the composition contain a total active herbicide loading of glyphosate salt and dicamba salt of at least about 450 grams acid equivalent per liter; (ii) the pH of the concentrate composition is less than about 5.7; and (iii) the acid equivalent weight ratio of glyphosate salt to dicamba salt is from about 1:1 to about 3:1.

Abstract: Provided are methods for preparing non-gelling, solubilized extracellular matrix (ECM) materials useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the non-gelling, solubilized ECM composition is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. In another embodiment, the composition is delivered intraarticularly, intrathecally, intraoccularly, intracranially, and into pleural space.

Abstract: Accordingly, the present invention provides a pharmaceutical oil-in-water nano-emulsion, with a pharmaceutically active substance. The selected pharmaceutically active substance is encased in monounsaturated fatty acid droplets with the droplets having an average particle size in the range of 60 to 200 nm. The nano-emulsion is also provided with a non-ionic surfactant system, which is a mixture of polyethers, macrogolglycerides and polysaccharides, along with pharmaceutically acceptable adjuvants. The present invention also provides a process for the preparation of pharmaceutical oil-in-water nano-emulsion.

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Abstract: The present invention relates to a process for preparing self-binding pigment particles comprising the following steps: a) providing an aqueous mineral pigment material suspension; b) providing at least one polymeric binder, wherein the binder comprises at least one modified polysaccharide having a degree of carboxylation in the range of 0.4 to 2.0 and having an intrinsic viscosity in the range of >300 to 500 ml/g, c) mixing the binder of step b) with the aqueous mineral pigment material suspension of step a) and adjusting the solids content of the obtained suspension so that it is >45 to 95 wt.-%, preferably from 45 to 80 wt.-%, based on the total weight of the suspension, and d) grinding the aqueous mineral material suspension of step c).

Abstract: Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients in the aggregate percentage of Group B ingredients present must be at least equal to the expression (2*/10?A %) where A % is the total percentage of Group A ingredients in the composition.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting ?2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.